Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.071
Filter
1.
BMJ Case Rep ; 17(6)2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38839418

ABSTRACT

A female underwent arthroscopic anterior cruciate ligament reconstruction (ACLR) via an outside-in drilling technique. At 4 weeks after surgery, she presented with a pulsatile painful mass on the lateral femoral condyle. Imaging confirmed a superolateral genicular artery pseudoaneurysm. Thrombin injections were administered twice, resulting in reduced size and minimal pain. This case emphasises the rare occurrence of pseudoaneurysms post-ACLR and highlights the importance of early detection and intervention for vascular complications. Although debated, we suggest tourniquet deflation before closure to facilitate identification and management of vascular issues. This report contributes valuable insights into managing pseudoaneurysms following ACLR.


Subject(s)
Aneurysm, False , Anterior Cruciate Ligament Reconstruction , Humans , Aneurysm, False/etiology , Aneurysm, False/diagnostic imaging , Aneurysm, False/surgery , Female , Anterior Cruciate Ligament Reconstruction/adverse effects , Anterior Cruciate Ligament Reconstruction/methods , Adult , Arthroscopy/adverse effects , Arthroscopy/methods , Postoperative Complications , Thrombin/administration & dosage , Anterior Cruciate Ligament Injuries/surgery
2.
J Thromb Haemost ; 22(5): 1389-1398, 2024 May.
Article in English | MEDLINE | ID: mdl-38278416

ABSTRACT

BACKGROUND: Iatrogenic femoral artery pseudoaneurysm (IFP) incidence is increasing with increase in diagnostic and therapeutic angiography, and so, the less invasive percutaneous thrombin injection (PTI) is the most widely used treatment. Moreover, studies that minimize PTI complications and highlight therapeutic effects are lacking. OBJECTIVES: This study performed in vitro thrombosis modeling of pseudoaneurysms and analyzed thrombosis within and thromboembolism outside the sac during thrombin injection. METHODS: We evaluated PTI in terms of thrombin injection location (at the junction of the IFP sac and neck, the center, and the dome, located farthest from the neck of the sac), thrombin injection time (5 and 8 seconds), and blood flow rate (ranging from 210 mL/min to 300 mL/min). Porcine blood was used as the working fluid in this study. RESULTS: Thrombin injection at the junction of the IFP sac and the pseudoaneurysm neck led to less thrombosis within the sac but substantial thrombi consistently outside the sac, whereas thrombin injected at the sac center mostly led to complete thrombosis within the sac, preventing further blood flow into the sac and reducing likelihood of thrombi outside the sac. A longer thrombin injection time enhanced the therapeutic effect and decreased the possibility of thromboembolism. Thromboembolism occurred more frequently at flow rates of >240 mL/min. CONCLUSION: The thrombin injection site in a pseudoaneurysm significantly influences thrombogenesis within and thromboembolism outside the sac. Thus, slow and deliberate injection of thrombin into the center of the sac could potentially reduce complications and enhance treatment efficacy.


Subject(s)
Aneurysm, False , Femoral Artery , Thrombin , Thrombosis , Thrombin/administration & dosage , Aneurysm, False/drug therapy , Animals , Thrombosis/drug therapy , Thrombosis/etiology , Swine , Injections, Intra-Arterial , Time Factors , Humans , Thromboembolism/drug therapy , Thromboembolism/prevention & control , Thromboembolism/etiology , Iatrogenic Disease
3.
Vasc Endovascular Surg ; 58(5): 530-534, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38153161

ABSTRACT

This report demonstrates the successful treatment of a carotid artery pseudoaneurysm using percutaneous thrombin injection. The patient, a 62-year-old woman with multiple comorbidities, experienced a pseudoaneurysm following an unintentional carotid artery puncture during a failed attempt to place a triple lumen catheter in the right jugular vein. Percutaneous thrombin injection was chosen as the treatment method, with Doppler ultrasound monitoring. Follow-up examinations showed no signs of recurrence, and the patient was discharged after nine days without complications.


Subject(s)
Carotid Artery Injuries , Iatrogenic Disease , Punctures , Thrombin , Vascular System Injuries , Humans , Thrombin/administration & dosage , Female , Middle Aged , Treatment Outcome , Carotid Artery Injuries/diagnostic imaging , Carotid Artery Injuries/drug therapy , Carotid Artery Injuries/etiology , Vascular System Injuries/diagnostic imaging , Vascular System Injuries/etiology , Vascular System Injuries/drug therapy , Aneurysm, False/diagnostic imaging , Aneurysm, False/drug therapy , Aneurysm, False/etiology , Hemostatics/administration & dosage , Hemostatics/adverse effects , Catheterization, Central Venous/adverse effects , Catheterization, Central Venous/instrumentation , Jugular Veins/diagnostic imaging , Computed Tomography Angiography , Ultrasonography, Doppler
4.
J Mater Sci Mater Med ; 32(10): 127, 2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34591193

ABSTRACT

Topical hemostatic agents have become essential tools to aid in preventing excessive bleeding in surgical or emergency settings and to mitigate the associated risks of serious complications. In the present study, we compared the hemostatic efficacy of SURGIFLO® Hemostatic Matrix Kit with Thrombin (Surgiflo-flowable gelatin matrix plus human thrombin) to HEMOBLAST™ Bellows Hemostatic Agent (Hemoblast-a combination product consisting of collagen, chondroitin sulfate, and human thrombin). Surgiflo and Hemoblast were randomly tested in experimentally induced bleeding lesions on the spleens of four pigs. Primary endpoints included hemostatic efficacy measured by absolute time to hemostasis (TTH) within 5 min. Secondary endpoints included the number of product applications and the percent of product needed from each device to achieve hemostasis. Surgiflo demonstrated significantly higher hemostatic efficacy and lower TTH (p < 0.01) than Hemoblast. Surgiflo-treated lesion sites achieved hemostasis in 77.4% of cases following a single product application vs. 3.3% of Hemoblast-treated sites. On average, Surgiflo-treated sites required 63% less product applications than Hemoblast-treated sites (1.26 ± 0.0.51 vs. 3.37 ± 1.16). Surgiflo provided more effective and faster hemostasis than Hemoblast. Since both products contain thrombin to activate endogenous fibrinogen and accelerate clot formation, the superior hemostatic efficacy of Surgiflo in the porcine spleen punch biopsy model seems to be due to Surgiflo's property as a malleable barrier able to adjust to defect topography and to provide an environment for platelets to adhere and aggregate. Surgiflo combines a flowable gelatin matrix and a delivery system well-suited for precise application to bleeding sites where other methods of hemostasis may be impractical or ineffective.


Subject(s)
Hemorrhage/therapy , Hemostatic Techniques , Hemostatics/administration & dosage , Spleen/drug effects , Administration, Topical , Animals , Biopsy/adverse effects , Biopsy/veterinary , Disease Models, Animal , Female , Gelatin/administration & dosage , Gelatin/pharmacology , Hemostasis, Surgical/methods , Hemostatics/pharmacology , Severity of Illness Index , Spleen/pathology , Swine , Thrombin/administration & dosage , Thrombin/pharmacology , Treatment Outcome
5.
Sci Rep ; 11(1): 16678, 2021 08 17.
Article in English | MEDLINE | ID: mdl-34404860

ABSTRACT

Ultrasound-guided thrombin injection (UGTI) is often the first-line treatment for iatrogenic post-catheterization pseudoaneurysms (psA). There are also first reports of the use of biologically derived tissue glues (TG) instead of sole thrombin especially when UGTI was unsuccessful or in case of psA recurrence. Previously, we have established that a late to early velocity index (LEVI) < 0.2 could be a predictor of an increased risk of psA recurrence after standard UGTI. In this paper, we report our first experiences when the choice of the first-line treatment method was based on LEVI assessment. From May 2017 till January 2020 we included 36 patients with psA. Of them, 10 had LEVI < 0.2 and they underwent ultrasound-guided tissue glue injection (UGTGI) with biological TG and 26 had LEVI > 0.2 and they underwent UGTI. The injection set containing human thrombin and fibrinogen was used for UGTGI. Bovine thrombin was used for UGTI. The success rate was 100% and no psA recurrence was detected during a 2-week follow-up. It was significantly better when compared to the expected recurrence rates based on our previous 14 years of experience (0% vs. 13%, p = 0.01). All complications (10% in the UGTGI group and 15% in the UGTI group) were mild and transient and included clinical symptoms of paresthesia, numbness, tingling, or pain. Their rates were comparable to the rates we previously reported. No significant differences in other characteristics were observed. The approach to choose the first-line treatment method for iatrogenic psA based on LEVI is encouraging. It may increase the success rate and avoid unnecessary repetition of the procedure, without increasing complication rate while keeping costs of the procedure reasonable.


Subject(s)
Aneurysm, False/therapy , Aged , Aged, 80 and over , Aneurysm, False/etiology , Animals , Catheterization/adverse effects , Cattle , Female , Fibrinogen/administration & dosage , Fibrinogen/therapeutic use , Hemostatics/administration & dosage , Hemostatics/therapeutic use , Humans , Injections , Male , Middle Aged , Prospective Studies , Thrombin/administration & dosage , Thrombin/therapeutic use , Ultrasonography, Interventional
6.
Korean J Radiol ; 22(11): 1834-1840, 2021 11.
Article in English | MEDLINE | ID: mdl-34402241

ABSTRACT

OBJECTIVE: To analyze the computational fluid dynamics (CFD) of femoral artery pseudoaneurysm (FAP), identify a suitable location and timing for percutaneous thrombin injection (PTI) based on this analysis, and report our clinical experience with the procedure. MATERIALS AND METHODS: CFD can be used to analyze the hemodynamics of the human body. An analysis using CFD recommended that the suitable location of the needle tip for PTI is at the center of the aneurysm sac and the optimal timing for starting PTI is during the early inflow phase of blood into the sac. Since 2011, seven patients (three male and four female; median age, 60 years [range, 43-75 years]) with FAP were treated with PTI based on the devised suitable location and time. Prior to the procedure, color Doppler ultrasonography was performed to determine the location and timing of the thrombin injection. RESULTS: The technical success rate of the PTI was 100%. The amount of thrombin used for the procedure ranged from 200 IU to 1000 IU (median, 500 IU). None of the patients experienced any symptoms or signs of embolic complications during the procedure. Follow-up CT images did not reveal any embolism in the lower extremities and showed complete thrombosis of the pseudoaneurysm. CONCLUSION: Based on our study of CFD, PTI administered centrally in the FAP during early inflow, as seen on color Doppler, can be an effective technique.


Subject(s)
Aneurysm, False , Thrombin , Adult , Aged , Aneurysm, False/diagnostic imaging , Aneurysm, False/drug therapy , Female , Femoral Artery/diagnostic imaging , Humans , Hydrodynamics , Male , Middle Aged , Thrombin/administration & dosage , Ultrasonography, Interventional
7.
Fluids Barriers CNS ; 18(1): 38, 2021 Aug 16.
Article in English | MEDLINE | ID: mdl-34399800

ABSTRACT

BACKGROUND: Thrombin has been implicated in playing a role in hydrocephalus development following intraventricular hemorrhage (IVH). However, the mechanisms underlying the sex differences to the detrimental effects of thrombin post-IVH remain elusive. METHOD: Three-month old male and female Sprague-Dawley rats underwent unilateral intracerebroventricular (ICV) injections of 3U or 5U thrombin, or saline, to examine differences in thrombin-induced hydrocephalus and white matter injury. Mortality, and lateral ventricle volume and white matter injury were measured on magnetic resonance imaging evaluation at 24 h post-injection. In addition, male rats were pretreated with 17-ß estradiol (E2, 5 mg/kg) or vehicle at 24 and 2 h prior to ICV injection of 3U thrombin. All rats were euthanized at 24 h post-injection for histology and immunohistochemistry. RESULTS: ICV injection of 5U thrombin caused 100 and 0% mortality in female and male rats, respectively. 3U of thrombin resulted in significant ventricular dilation and white matter damage at 24 h in both male and female rats, but both were worse in females (p < 0.05). Furthermore, neutrophil infiltration into choroid plexus and periventricular white matter was enhanced in female rats and may play a critical role in the sex difference in brain injury. Pre-treating male rats with E2, increased thrombin (3U)-induced hydrocephalus, periventricular white matter injury and neutrophil infiltration into the choroid plexus and white matter. CONCLUSIONS: ICV thrombin injection induced more severe ventricular dilation and white matter damage in female rats compared to males. Estrogen appears to contribute to this difference which may involve greater neutrophil infiltration in females. Understanding sex differences in thrombin-induced brain injury may shed light on future interventions for hemorrhagic stroke.


Subject(s)
Hydrocephalus/chemically induced , Hydrocephalus/pathology , Neutrophils/physiology , Sex Characteristics , Thrombin/toxicity , White Matter/pathology , Animals , Cerebral Ventricles/blood supply , Cerebral Ventricles/drug effects , Cerebral Ventricles/pathology , Choroid Plexus/blood supply , Choroid Plexus/drug effects , Choroid Plexus/pathology , Female , Injections, Intraventricular , Male , Rats , Rats, Sprague-Dawley , Thrombin/administration & dosage , White Matter/drug effects , White Matter/injuries
8.
J Vasc Surg ; 74(3): 1024-1032, 2021 09.
Article in English | MEDLINE | ID: mdl-33940072

ABSTRACT

OBJECTIVE: The long-term success of endovascular aneurysm repair (EVAR) is limited by complications, most importantly endoleaks. In case of (persistent) type I endoleak (T1EL), secondary intervention is indicated to prevent secondary aneurysm rupture. Different treatment options are suggested for T1ELs, such as endo anchors, (fenestrated) cuffs, embolization, or open conversion. Currently, the treatment of T1EL with liquid embolic agents is available; however, results are not yet addressed. This review presents the safety and efficacy of embolization with liquid embolic agents for treatment of T1ELs after EVAR. METHODS: A systematic literature search was performed for all studies reporting the use of liquid embolic agents as monotherapy for treatment of T1ELs after EVAR. Patient numbers, technical success (successful delivery of liquid embolics in the T1EL) and clinical success (absence of aneurysm related death, endoleak recurrence or additional interventions during follow-up) were examined. RESULTS: Of 1604 articles, 10 studies met the selection criteria, including 194 patients treated with liquid embolics; 73.2% of the patients were male with a median age of 71 years. The overall technical success was 97.9%. Clinical success was 87.6%. Because the median follow-up was only 13.0 months (range, 1-89 months), data on long-term success are almost absent. Four cases (2.1%) of secondary aneurysm rupture after embolization owing to endoleak recurrence were reported. All ruptures occurred in aneurysms exceeding initial treatment diameter of 70 mm. CONCLUSIONS: Initial technical success after liquid embolization for T1EL is high, although long-term clinical success rates are lacking. Within this review, the risk of secondary rupture is comparable with untreated T1EL at 2% with a median follow-up of 13 months, regardless of the initial success of embolization. In general, no decrease in secondary aneurysm rupture after embolization of T1EL after EVAR is demonstrated, although the results of late embolization are debated.


Subject(s)
Aortic Aneurysm, Abdominal/surgery , Blood Vessel Prosthesis Implantation/adverse effects , Embolization, Therapeutic , Endoleak/therapy , Endovascular Procedures/adverse effects , Aged , Aged, 80 and over , Aortic Aneurysm, Abdominal/mortality , Blood Vessel Prosthesis Implantation/mortality , Dimethyl Sulfoxide/administration & dosage , Embolization, Therapeutic/adverse effects , Embolization, Therapeutic/mortality , Enbucrilate/administration & dosage , Endoleak/diagnostic imaging , Endoleak/etiology , Endoleak/mortality , Endovascular Procedures/mortality , Female , Humans , Male , Polyvinyls/administration & dosage , Risk Assessment , Risk Factors , Thrombin/administration & dosage , Time Factors , Treatment Outcome
9.
Bioengineered ; 12(1): 815-820, 2021 12.
Article in English | MEDLINE | ID: mdl-33645436

ABSTRACT

This study aimed to assess the effectiveness and safety of intravesical instillation treatment of Kangfuxin liquid (KFL) combined with thrombin and epidermal growth factor (EGF) for radiation-induced hemorrhagic cystitis (HC) in patients with cervical cancer. A total of 34 patients with radiation-induced HC of grade 2-4 were treated with intravesical instillation of KFL combined with thrombin and EGF until the complete disappearance of hematuria and lower urinary tract symptoms (LUTS). Gentamicin was added if white blood cells were detected and bacterial culture was positive in the urine. All patients were followed up for 2 years to evaluate the clinical efficacy and safety of the treatment regimen. Patients with and without recurrent hematuria (n = 3, 9% and n = 31, 91%, respectively) were completely recovered from hematuria and LUTS by intravesical instillation treatment for 6-22 days. No adverse event was reported during the treatment and the 2-year follow-up for all patients. Thus, intravesical instillation of KFL combined with thrombin and EGF is an effective and safe therapeutic regimen for radiation-induced HC of grade 2-4 in patients with cervical cancer.


Subject(s)
Cystitis , Hemorrhage , Materia Medica , Radiotherapy/adverse effects , Uterine Cervical Neoplasms/radiotherapy , Administration, Intravesical , Adult , Aged , Cystitis/drug therapy , Cystitis/etiology , Epidermal Growth Factor/administration & dosage , Epidermal Growth Factor/therapeutic use , Female , Hemorrhage/drug therapy , Hemorrhage/etiology , Hemostatics/administration & dosage , Hemostatics/therapeutic use , Humans , Materia Medica/administration & dosage , Materia Medica/therapeutic use , Middle Aged , Radiation Injuries/drug therapy , Radiation Injuries/etiology , Thrombin/administration & dosage , Thrombin/therapeutic use
10.
Pol Przegl Chir ; 93(1): 49-54, 2021 Feb 26.
Article in English | MEDLINE | ID: mdl-33729174

ABSTRACT

Haemostatic materials such as: gelatine sponges, oxygenated cellulose meshes, tissue sealants, collagen matrices with human thrombin and fibrinogen are gaining on popularity in gastrointestinal surgery, especially in colorectal surgery. We searched for available scientific publications in the Pubmed and Cochrane database on the use of individual hemostatic materials in the field of gastrointestinal surgery. The analysis focused on the assessment of the safety of the use of individual materials in terms of the rate of bleeding complications and the rate of anastomotic leakage cases. The use of haemostatic materials has for years been a recognized method of reducing the rate of intra- and postoperative complications, both in gastrointestinal surgery and in other surgical specialties. Based on the available studies, it can be concluded that the use of hemostatic materials such as matrices, sponges and adhesives in gastrointestinal surgery, even in patients at high risk of anastomotic leakage and bleeding complications, reduces the incidence of complications. The growing popularity of haemostatics and sealants in surgery means that they are currently used in a wide range of indications, and surgeons are more and more willing to use them even in case of standard surgical procedures, which is reflected in the available studies. Choosing a haemostat should be a conscious decision, taking into account the site and type of bleeding, mechanism of action, ease of use, efficacy, safety, and price, among others.


Subject(s)
Digestive System Surgical Procedures/methods , Hemostasis, Surgical/methods , Hemostatics/administration & dosage , Postoperative Hemorrhage/prevention & control , Thrombin/administration & dosage , Anastomotic Leak/prevention & control , Fibrinogen , Humans
11.
Clin Radiol ; 76(4): 314.e17-314.e23, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33526255

ABSTRACT

AIM: To analyse the technical challenges, clinical success, and associated complications of endovascular and percutaneous embolisation of pancreatitis-related pseudoaneurysms. MATERIALS AND METHODS: A retrospective study of patients referred for embolisation of pancreatitis-related pseudoaneurysms between January 2014 and March 2019 was conducted. Computed tomography angiography (CTA) was performed to assess the morphology of the aneurysms prior to any intervention. Percutaneous or endovascular embolisation was performed. Details of CTA and methods of embolisation were recorded. Technical success, clinical success, and complications were reported. RESULTS: A total of 80 patients (mean age, 40.69 ± 13.41 years, 73 male) underwent embolisation during the study period. Pseudoaneurysms were related to chronic pancreatitis (CP) in 44 (55%) patients and acute pancreatitis (AP) in 36 (45%) patients. Pseudoaneurysms were detected in 65 (81.2%) patients on CTA. The most common site of pseudoaneurysms was gastroduodenal artery (GDA) followed by splenic artery. Seven patients were treated with percutaneous thrombin injection and five were treated with percutaneous glue injection under ultrasound/fluoroscopy guidance. The remaining patients (n=68) underwent catheter angiography with endovascular embolisation. Technical success was achieved in 4/7 (57%) percutaneous thrombin cases and in all the cases (5/5, 100%) with percutaneous glue or endovascular (68/68,100%) embolisation. CONCLUSION: Endovascular or percutaneous embolisation of pseudoaneurysms has high technical success with an excellent safety profile.


Subject(s)
Aneurysm, False/therapy , Embolization, Therapeutic/methods , Endovascular Procedures/methods , Pancreatitis/complications , Acute Disease , Adolescent , Adult , Aged , Aneurysm, False/diagnostic imaging , Aneurysm, False/etiology , Arteries/diagnostic imaging , Child , Computed Tomography Angiography , Duodenum/blood supply , Embolization, Therapeutic/adverse effects , Endovascular Procedures/adverse effects , Female , Fibrin Tissue Adhesive/administration & dosage , Gastric Artery/diagnostic imaging , Humans , India , Male , Middle Aged , Pancreatitis, Chronic/complications , Recurrence , Retrospective Studies , Splenic Artery/diagnostic imaging , Tertiary Care Centers , Thrombin/administration & dosage , Young Adult
12.
Int J Med Sci ; 18(3): 756-762, 2021.
Article in English | MEDLINE | ID: mdl-33437210

ABSTRACT

Background: Curing hemorrhagic cystitis remains a challenge. We explore a continuous and effective treatment for hemorrhagic radiation cystitis. Methods: The data of patients in 6 provincial cancer hospital urology departments between April 2015 and December 2019 was reviewed retrospectively. Patients were classified as moderate and severe groups. The 5-steps sequential method was adopted. Two groups were initiated with step 1 and step 3 respectively. Step 1 was symptomatic treatment. Thrombin solution or sodium hyaluronate was administrated for bladder irrigation in step 2. Step 3 was transurethral electrocoagulation. Step 4 was interventional embolization. Step 5 was HBO therapy. OABSS was used to assess the improvement of patients' symptoms. The outcome was evaluated after at least 6 months of follow-up. Results: A total of 650 patients (56 men and 594 women), mean age 71.2 years, were enrolled in the 5 steps sequential method. 582 patients were classified as moderate and 68 severe group. In moderate group, the cure rate of step 1 was 61.2% (356/582), 80.4% (468/582) after step 2, 93.1% (542/582) after step 3, 96.2% (560/582) after step 4, and 99.8% (581/582) after step 5. In severe group, the cure rate was 54.4% (37/68) after step 3, 76.5% (52/68) after step 4, and 94.1% (64/68) after the step 5 respectively. The mean OABSS scores of both groups significantly decreased after 5 steps sequential method treatment (P<0.01). Conclusions: Our results show hemorrhagic radiation cystitis can be cured in 5 steps, and the 5 steps sequential method is welcomed and effective. Therapy efficacy depends on the number of steps adopted and the severity of hematuria.


Subject(s)
Critical Pathways , Cystitis/therapy , Hematuria/therapy , Pelvic Neoplasms/radiotherapy , Radiation Injuries/therapy , Administration, Intravesical , Aged , Cystitis/diagnosis , Cystitis/etiology , Cystitis/urine , Electrocoagulation/methods , Embolization, Therapeutic/methods , Female , Hematuria/diagnosis , Hematuria/etiology , Hematuria/urine , Humans , Hyaluronic Acid/administration & dosage , Hyperbaric Oxygenation/methods , Male , Radiation Injuries/diagnosis , Radiation Injuries/etiology , Radiation Injuries/urine , Retrospective Studies , Severity of Illness Index , Thrombin/administration & dosage , Treatment Outcome
13.
J Clin Ultrasound ; 49(4): 385-389, 2021 May.
Article in English | MEDLINE | ID: mdl-32929773

ABSTRACT

Uterine artery pseudoaneurysm is an uncommon but important cause of severe uterine bleeding in the postpartum or postsurgical setting. The standard treatment options are endovascular uterine artery embolization and bilateral surgical internal iliac artery ligation for uterus conservation or hysterectomy. We report the case of a young female with hemorrhage from an intramyometrial pseudoaneurysm following repeated curettage and hysteroscopic excision of retained products of conception. Uterus preservation was of priority, and the patient underwent uterine artery embolization; however, the pseudoaneurysm persisted due to ovarian artery collaterals. The pseudoaneurysm was subsequently treated with transvaginal ultrasound-guided direct thrombin injection. The case highlights the advantages and disadvantages of the treatment options in such clinically challenging cases emphasizing the seldom employed direct injection of thrombin for the treatment of pseudoaneurysms.


Subject(s)
Aneurysm, False/drug therapy , Thrombin/administration & dosage , Uterine Hemorrhage/diagnostic imaging , Uterine Hemorrhage/drug therapy , Adult , Aneurysm, False/diagnostic imaging , Female , Humans , Hysterectomy , Treatment Failure , Ultrasonography/methods , Ultrasonography, Interventional/methods , Uterine Artery/diagnostic imaging , Uterine Artery Embolization , Uterine Hemorrhage/etiology , Uterus/blood supply
14.
Oral Oncol ; 112: 104986, 2021 01.
Article in English | MEDLINE | ID: mdl-32873463

ABSTRACT

Intraoperative rupture of a pleomorphic adenoma capsule with potential tumor spillage into the surgical field is thought to occur in approximately 5% of cases and has traditionally been recognized as one of the major causes of recurrence. It seems that recurrence of a pleomorphic adenoma is a multifactorial event, being related to surgery (capsular exposure, tumor spillage) and tumor-related factors (histologic subtype, incomplete capsule, pseudopodia, satellites). The exact quantities of these ingredients in the recipe of recurrence, as well as possible interactions between them (e.g. the potentially increased fragility of myxoid pleomorphic adenomas; satellites or pseudopodia being cut off the tumor specimen during an extremely narrow extracapsular dissection) remain unclear. A thorough literature search did not reveal any proposed algorithms for the intraoperative management of a capsular tear. The aim of this short communication is to present our department's experience-based proposal for intraoperative measures in the case of macroscopic rupture and tumor spillage of a parotid gland pleomorphic adenoma.


Subject(s)
Adenoma, Pleomorphic/surgery , Intraoperative Care/methods , Intraoperative Complications/pathology , Neoplasm Recurrence, Local/etiology , Parotid Neoplasms/surgery , Salivary Gland Neoplasms/surgery , Adenoma, Pleomorphic/pathology , Algorithms , Contraindications, Procedure , Dissection/adverse effects , Dissection/methods , Drug Combinations , Fibrinogen/administration & dosage , Humans , Neoplasm Seeding , Parotid Gland/surgery , Postoperative Period , Pseudopodia , Rupture/therapy , Salivary Gland Neoplasms/pathology , Surgical Wound , Therapeutic Irrigation/adverse effects , Thrombin/administration & dosage , Truth Disclosure
15.
J Gynecol Obstet Hum Reprod ; 50(7): 101994, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33217600

ABSTRACT

OBJECTIVE: To evaluate a thrombin gel matrix (TGM), Floseal, for the prevention of lymphocele in patients with endometrial cancer who underwent pelvic lymphadenectomy. METHODS: A total of 79 consecutive patients with endometrial cancer were randomly allocated to one of two groups: the TGM group and control group. After completion of the lymphadenectomy, 5 mL of Floseal was applied to the bilateral pelvic sidewalls, especially the femoral canal, obturator, and common iliac vessels areas. Computed tomography scans were obtained for lymphocele evaluation 2 months after the surgery. RESULTS: Three patients from the TGM group, and four patients from the control group were lost during follow-up, and data from 36 participants from each group were analyzed. As the primary outcome, lymphocele developed in 12 patients in both groups (33 %). There was no significant difference between the groups in terms of lymphocele and symptomatic lymphocele development. Lymphocele localization was also not different between the two groups, but the diameter of the lymphoceles detected in the TGM group was significantly greater (p = 0.021). The mean drainage days was significantly shorter in the TGM group (p = 0.015). The amount of drainage was also less in the TGM group, but the difference was not statistically significant. CONCLUSION: Thrombin gel matrix applied to the pelvic sidewalls does not reduce the incidence of symptomatic or asymptomatic lymphoceles after pelvic lymphadenectomy in endometrial cancer. However, it can reduce the amount of drainage and the number of drainage days so it can help to shorten hospitalization.


Subject(s)
Endometrial Neoplasms/drug therapy , Gelatin Sponge, Absorbable/therapeutic use , Lymphocele/prevention & control , Aged , Endometrial Neoplasms/complications , Female , Gelatin Sponge, Absorbable/administration & dosage , Humans , Incidence , Lymph Node Excision/methods , Lymphocele/drug therapy , Middle Aged , Prospective Studies , Thrombin/administration & dosage , Thrombin/therapeutic use
16.
J Clin Ultrasound ; 49(4): 390-394, 2021 May.
Article in English | MEDLINE | ID: mdl-33098132

ABSTRACT

A 27-year-old man, previously diagnosed with IgA nephropathy, was referred for native kidney biopsy. After the procedure, the patient presented active bleeding revealed by Doppler and contrast-enhanced ultrasonography at the biopsy site. Successful embolization of the cortical fistula, the focus of bleeding, was achieved using ultrasound-guided thrombin injection and confirmed by Doppler ultrasonography, contrast-enhanced ultrasonography, and CT angiography. This case report shows that contrast-enhanced ultrasonography is useful for detecting active bleeding after a solid organ biopsy. Moreover, ultrasound-guided thrombin embolization is a safe and minimally invasive treatment and an alternative to angiography-guided embolization.


Subject(s)
Aneurysm, False/therapy , Biopsy/adverse effects , Embolization, Therapeutic/methods , Hematoma/therapy , Hemorrhage/therapy , Kidney Diseases/therapy , Thrombin/administration & dosage , Adult , Aneurysm, False/diagnostic imaging , Aneurysm, False/etiology , Angiography/methods , Hematoma/diagnostic imaging , Hematoma/etiology , Hemorrhage/diagnostic imaging , Hemorrhage/etiology , Humans , Kidney/blood supply , Kidney/pathology , Kidney Diseases/diagnostic imaging , Kidney Diseases/etiology , Male , Ultrasonography, Interventional/methods
17.
Proc Natl Acad Sci U S A ; 117(46): 28667-28677, 2020 11 17.
Article in English | MEDLINE | ID: mdl-33139557

ABSTRACT

The treatment of diabetic ulcer (DU) remains a major clinical challenge due to the complex wound-healing milieu that features chronic wounds, impaired angiogenesis, persistent pain, bacterial infection, and exacerbated inflammation. A strategy that effectively targets all these issues has proven elusive. Herein, we use a smart black phosphorus (BP)-based gel with the characteristics of rapid formation and near-infrared light (NIR) responsiveness to address these problems. The in situ sprayed BP-based gel could act as 1) a temporary, biomimetic "skin" to temporarily shield the tissue from the external environment and accelerate chronic wound healing by promoting the proliferation of endothelial cells, vascularization, and angiogenesis and 2) a drug "reservoir" to store therapeutic BP and pain-relieving lidocaine hydrochloride (Lid). Within several minutes of NIR laser irradiation, the BP-based gel generates local heat to accelerate microcirculatory blood flow, mediate the release of loaded Lid for "on-demand" pain relief, eliminate bacteria, and reduce inflammation. Therefore, our study not only introduces a concept of in situ sprayed, NIR-responsive pain relief gel targeting the challenging wound-healing milieu in diabetes but also provides a proof-of-concept application of BP-based materials in DU treatment.


Subject(s)
Diabetic Foot/therapy , Phosphorus/administration & dosage , Photothermal Therapy , Smart Materials/administration & dosage , Wound Healing/drug effects , Anesthetics, Local/administration & dosage , Animals , Cell Line , Cell Proliferation/drug effects , Diabetes Mellitus, Experimental , Drug Evaluation, Preclinical , Endothelial Cells/drug effects , Fibrinogen/administration & dosage , Gels , Human Umbilical Vein Endothelial Cells , Humans , Lidocaine/administration & dosage , Male , Mice, Inbred BALB C , Neovascularization, Physiologic/drug effects , Thrombin/administration & dosage
18.
Nat Commun ; 11(1): 4907, 2020 09 30.
Article in English | MEDLINE | ID: mdl-32999289

ABSTRACT

Global alterations in the metabolic network provide substances and energy to support tumor progression. To fuel these metabolic processes, extracellular matrix (ECM) plays a dominant role in supporting the mass transport and providing essential nutrients. Here, we report a fibrinogen and thrombin based coagulation system to construct an artificial ECM (aECM) for selectively cutting-off the tumor metabolic flux. Once a micro-wound is induced, a cascaded gelation of aECM can be triggered to besiege the tumor. Studies on cell behaviors and metabolomics reveal that aECM cuts off the mass transport and leads to a tumor specific starvation to inhibit tumor growth. In orthotopic and spontaneous murine tumor models, this physical barrier also hinders cancer cells from distant metastasis. The in vivo gelation provides an efficient approach to selectively alter the tumor mass transport. This strategy results in a 77% suppression of tumor growth. Most importantly, the gelation of aECM can be induced by clinical operations such as ultrasonic treatment, surgery or radiotherapy, implying this strategy is potential to be translated into a clinical combination regimen.


Subject(s)
Biomimetic Materials/administration & dosage , Extracellular Matrix/chemistry , Neoplasms/therapy , Animals , Biological Transport/drug effects , Biological Transport/radiation effects , Biomimetic Materials/chemistry , Biomimetic Materials/radiation effects , Cell Line, Tumor/transplantation , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Chemoradiotherapy/methods , Disease Models, Animal , Extracellular Matrix/metabolism , Extracellular Matrix/radiation effects , Female , Fibrinogen/administration & dosage , Fibrinogen/chemistry , Fibrinogen/radiation effects , Gels , Humans , Injections, Intravenous , Metabolomics , Mice , Neoplasms/metabolism , Thrombin/administration & dosage , Thrombin/chemistry , Thrombin/radiation effects , Ultrasonic Therapy/methods , Ultrasonic Waves
19.
Clin Appl Thromb Hemost ; 26: 1076029620954913, 2020.
Article in English | MEDLINE | ID: mdl-33030036

ABSTRACT

INTRODUCTION: Sulodexide represents a mixture of fast-moving heparin (FMH) and dermatan sulfate (DS) and has been used for the management of venous diseases such as DVT and related disorders. The purpose of this study is to compare sulodexide and its components with unfractionated heparin (UFH) to determine its suitability for the indications in which UFH is used. MATERIALS AND METHOD: Active pharmaceutical ingredients (API) versions of sulodexide, FMH and DS were obtained from Alfasigma. API versions of UFH were obtained from Medefil Inc. Normal human citrated plasma was obtained from blood bank of the Loyola University Medical Center. Each of the individual agents were supplemented in plasma at a graded concentration of 0.0-10 µg/mL. Clotting assays (PiCT, aPTT, PT and TT), anti-Xa and anti-IIa and thrombin generation studies were carried out. Results were compiled as mean ± SD of 3 individual determination. RESULT: In the clot based (PiCT, aPTT and TT), anti-Xa and IIa assays, both the UFH and FMH produced stronger activities in these assays followed by sulodexide. DS did not show any anticoagulant activity. In the thrombin generation assay, FMH and UFH produced comparable inhibition of thrombin generation as measured by various parameters. Sulodexide was slightly weaker in this assay, whereas DS produced relatively weaker effects. CONCLUSION: In comparison to sulodexide, both UFH and FMH exhibit comparable anticoagulant activity despite differences in their molecular weight. These results suggest that sulodexide can be developed as a parenteral anticoagulant for indications in which UFH is used.


Subject(s)
Anticoagulants/pharmacology , Blood Coagulation/drug effects , Glycosaminoglycans/pharmacology , Thrombin/pharmacology , Anticoagulants/administration & dosage , Antithrombins/administration & dosage , Antithrombins/pharmacology , Glycosaminoglycans/administration & dosage , Heparin/administration & dosage , Heparin/pharmacology , Humans , Italy , Sensitivity and Specificity , Thrombin/administration & dosage
20.
Sci Rep ; 10(1): 17318, 2020 10 14.
Article in English | MEDLINE | ID: mdl-33057149

ABSTRACT

Modeling stroke in animals is essential for testing efficacy of new treatments; however, previous neuroprotective therapies, based on systemic delivery in rodents failed, exposing the need for model with improved clinical relevance. The purpose of this study was to develop endovascular approach for inducing ischemia in swine. To achieve that goal, we used intra-arterial administration of thrombin mixed with gadolinium and visualized the occlusion with real-time MRI. Placement of the microcatheter proximally to rete allowed trans-catheter perfusion of the ipsilateral hemisphere as visualized by contrast-enhanced perfusion MR scans. Dynamic T2*w MRI facilitated visualization of thrombin + Gd solution transiting through cerebral vasculature and persistent hyperintensities indicated occlusion. Area of trans-catheter perfusion dynamically quantified on representative slice before and after thrombin administration (22.20 ± 6.31 cm2 vs. 13.28 ± 4.71 cm2 respectively) indicated significantly reduced perfusion. ADC mapping showed evidence of ischemia as early as 27 min and follow-up T2w scans confirmed ischemic lesion (3.14 ± 1.41 cm2). Animals developed contralateral neurological deficits but were ambulatory. Our study has overcome long lasting challenge of inducing endovascular stroke model in pig. We were able to induce stroke using minimally invasive endovascular approach and observe in real-time formation of the thrombus, blockage of cerebral perfusion and eventually stroke lesion.


Subject(s)
Brain/diagnostic imaging , Diffusion Tensor Imaging/methods , Image Processing, Computer-Assisted/methods , Ischemic Stroke/diagnostic imaging , Neuroimaging/methods , Thrombosis/diagnostic imaging , Animals , Contrast Media/administration & dosage , Disease Models, Animal , Gadolinium/administration & dosage , Male , Swine , Thrombin/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...